RenovaCare, Inc., announced that the company has bolstered its patent portfolio with the issuance of a United States patent for its novel SkinGun™ device. The United States Patent and Trademark Office has granted an additional 30-month extension for the patent, providing protection beyond the year 2035.
RenovaCare, Inc., announced the appointment of Roger Esteban-Vives, Ph.D. as Director of Cell Sciences.
RenovaCare, Inc., released behind–the–scenes video footage of its medical device for spraying a patient’s own stem cells onto burns and wounds for rapid self-healing. The footage includes compelling first-hand testimony and before-and-after images of a State Trooper’s rapid, scar-free recovery from severe burns to over one-third of his body.
RenovaCare, Inc., today announced positive spray test results demonstrating that its novel SkinGun™ technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods. These outcomes are especially promising to scientists developing patented RenovaCare CellMist™ and SkinGun™ technologies* for spraying fluids containing a patient’s own stem cells onto burns and wounds for rapid scar-free healing.
New York & Pittsburgh – May 3, 2016 – RenovaCare, Inc., (OTCQB: RCAR), a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies*, today announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin, one of the…
New York & Pittsburgh – April 12, 2016 – RenovaCare, Inc., a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that the company has successfully completed the engineering, studies, and associated efforts…
New York & Pittsburgh – February 9, 2016 – RenovaCare, Inc., developer of patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of Steven Q. Wang to its Board of Advisors. Dr. Wang is Head of Dermatology Section and…
New York & Pittsburgh – January 12, 2016 – RenovaCare, Inc., developer of the patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of board certified plastic and reconstructive surgeon, Richard Simman, MD, FACS, and FACCWS, to its Board…
New York & Pittsburgh, PA – November 17, 2015 – RenovaCare, Inc. (OTCQB: RCAR), today announced a partnership to validate the science behind its groundbreaking technology for treatments of wounds, burns and other skin defects. The company’s research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin,…
RenovaCare, Inc., (RCAR), developer of the patented CellMist™ and SkinGun™ technologies for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced the appointment of healthcare executive and industry thought-leader, Michael M. Barch, to its Board of Advisors. Barch currently serves as Chairman of the Board of the…